Bio-Rad Laboratories, Inc. Class A (BIO) Covered Calls
Bio-Rad Laboratories, Inc. is a global leader in life science research and clinical diagnostics. The company develops and manufactures a broad range of innovative products used to separate, identify, and analyze complex biological materials. In 2026, Bio-Rad is leveraging its acquisition of Stilla Technologies to lead the digital PCR market, providing critical tools for oncology research, cell and gene therapy, and infectious disease monitoring.
You can sell covered calls on Bio-Rad Laboratories, Inc. Class A to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for BIO (prices last updated Fri 4:16 PM ET):
| Bio-Rad Laboratories, Inc. Class A (BIO) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 287.84 | +6.42 | 225.00 | 293.47 | 211K | 10 | 7.6 |
| Covered Calls For Bio-Rad Laboratories, Inc. Class A (BIO) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| May 15 | 290 | 11.00 | 282.47 | 2.7% | 44.8% | |
| Jun 18 | 290 | 15.00 | 278.47 | 4.1% | 26.7% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Bio-Rad Laboratories, Inc. (BIO) operates as a dual-threat powerhouse in the healthcare sector. The company is split between its Life Science segment, which provides instruments and reagents for research, and its Clinical Diagnostics segment, which supplies test systems and quality controls to hospital laboratories. Bio-Rad is particularly noted for its "Droplet Digital PCR" (ddPCR) technology, which has become the gold standard for high-precision genetic analysis and liquid biopsy applications.
Core Business and Products
The company generates substantial recurring revenue from its massive installed base of diagnostic platforms. Its product portfolio includes QX700 ddPCR systems, chromatography instruments, and a leading suite of diabetes monitoring and blood typing tools. In early 2026, Bio-Rad successfully integrated Stilla Technologies, allowing the company to launch a new generation of digital PCR platforms that offer higher multiplexing capabilities. This segment is increasingly focused on "Biopharma" partnerships, where Bio-Rad tools are used to validate the efficacy of novel mRNA and CRISPR-based therapies.
Competitive Landscape
- Danaher Corporation is the primary heavyweight competitor, battling Bio-Rad across both life science research and clinical diagnostics markets.
- Agilent Technologies, Inc. competes directly in the laboratory instrumentation and analytical software space, particularly in chromatography and mass spectrometry.
- Illumina, Inc. is a significant rival in the genomics space; while Illumina dominates sequencing, Bio-Rad competes in the high-growth digital PCR niche for validation and monitoring.
- Revvity, Inc. competes in the life sciences and diagnostics industry, focusing on health science solutions that overlap with Bio-Rad’s specialty diagnostics.
- Bio-Techne Corporation provides high-quality reagents and instruments for the life sciences, competing for budget in academic and biopharma research labs.
Strategic Outlook and Innovation
The strategic focus for Bio-Rad in 2026 is "Margin Recovery and Portfolio Optimization." Following a mixed 2025 where research funding was constrained, the company raised its 2026 revenue guidance in February to a range of $2.60 billion to $2.62 billion. Management is prioritizing a 12% to 12.5% adjusted operating margin, driven by a rebound in "Clinical Diagnostics" demand in the Asia-Pacific region. A significant catalyst for the stock in 2026 is the monetization of its stake in Sartorius AG, which continues to provide Bio-Rad with a massive, albeit volatile, asset on its balance sheet.
Innovation at Bio-Rad is currently centered on "Multiplex Digital PCR." In 2026, the company launched the QX700 family of products, which allows researchers to detect more genetic targets in a single sample than ever before. Bio-Rad is also expanding its AI-driven "Unity Next" quality control software, which helps hospital labs automate the monitoring of their testing accuracy and regulatory compliance. By bridging the gap between basic research and clinical application with these high-precision tools, Bio-Rad aims to remain indispensable to the next generation of precision medicine.
| Top 10 Open Interest For May 15 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | TLT covered calls | 1. | POET covered calls | |
| 2. | SLV covered calls | 7. | HYG covered calls | 2. | CMPX covered calls | |
| 3. | IBIT covered calls | 8. | QQQ covered calls | 3. | TEAM covered calls | |
| 4. | GLD covered calls | 9. | KWEB covered calls | 4. | AAOI covered calls | |
| 5. | SPY covered calls | 10. | EEM covered calls | 5. | ENPH covered calls | |
Want more examples? BILS Covered Calls | BIOA Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
